Among nearly 2,000 cancer patients in Minnesota's medical cannabis program, higher CBD doses and enteral (swallowed) products were associated with the most improvement in anxiety—while depression responded mainly to how cannabis was taken, not the dose.
Cancer patients using cannabis for anxiety or depression, oncologists advising on cannabis product selection, and medical cannabis program designers.
What the researchers found
This longitudinal study followed 1,962 cancer patients enrolled in the Minnesota Medical Cannabis Program, measuring self-reported anxiety and depression before and after 30 days of use. It's one of the largest studies to break down cannabis effects by dose, THC:CBD ratio, and route of administration.
For anxiety, the findings were dose-specific: patients taking higher CBD doses (>14.3 mg/day) showed more improvement than those taking lower doses (<4.6 mg/day). The route also mattered—enteral products (swallowed oils, capsules, edibles) outperformed other administration routes. And the THC:CBD ratio was relevant, though the specific pattern required a nuanced look at the data.
Depression followed a different pattern. Dose and THC:CBD ratio didn't significantly predict depression improvement—only the route of administration mattered, with enteral products again showing the most benefit.
The divergence between anxiety and depression is interesting: anxiety responded to dose, ratio, and route, while depression responded only to route. This suggests different mechanisms—CBD's anxiolytic effects may be dose-dependent, while depression improvement may relate more to the pharmacokinetic profile of swallowed products (slower onset, longer duration) than to the specific cannabinoid content.
The fact that enteral products outperformed others for both conditions has practical implications: patients seeking mental health benefits may do better with oils and capsules than with inhaled products.
Why it matters
Cancer patients increasingly use cannabis for anxiety and depression, but most do so without evidence-based guidance on what type to use. This study provides the first large-scale data suggesting that higher CBD doses and swallowed products may be optimal for anxiety—actionable information for patients and the clinicians advising them.
The numbers in context
N = 1,962 cancer patients. 30-day follow-up. Higher CBD (>14.3 mg/day) better for anxiety than lower CBD (<4.6 mg/day). Enteral products better for both anxiety and depression. Depression responded to route but not dose or ratio.
How the study worked
Longitudinal cohort study. 1,962 cancer patients enrolled in the Minnesota Medical Cannabis Program. Self-reported anxiety and depression measured at enrollment and after 30 days. Analyzed by CBD dose (tertiles), THC:CBD ratio, and route of administration (enteral vs. other).
Who was studied
N=1,962 cancer patients, Minnesota, enrolled in the Medical Cannabis Program
What this study cannot tell us
Observational design within a medical cannabis program—patients chose their products (no randomization). Self-reported anxiety and depression (no clinical diagnosis). 30-day follow-up is relatively short. No control group (improvements could reflect placebo, natural recovery, or other treatments). Minnesota's program may have a specific product selection that limits generalizability. Dose data relies on product labels, not measured blood levels.
How to read the evidence
Large longitudinal cohort from a state medical cannabis program—real-world data with meaningful sample size but limited by observational design and self-selection.
When this study was published
Published in 2025 in Cancer Medicine, reflecting current medical cannabis product options.
The bigger picture
This fills a gap in the cancer-cannabis evidence. RTHC-00158's RCT found no overall symptom benefit but specific pain improvement from THC:CBD. RTHC-00177's qualitative data captured patient-perceived appetite benefits. This study adds the mental health dimension, showing that how and what cancer patients take matters for psychological outcomes. The finding that enteral products outperform also connects to the bioavailability research in RTHC-00179—swallowed products produce different pharmacokinetic profiles than inhaled ones.
Replication
Not stated in abstract.
Funding
Not reported in abstract.
Conflicts of interest
Not reported in abstract.
Questions still open
- Would a longer follow-up show sustained anxiety and depression benefits? Why does route matter more than dose for depression? Would these findings replicate in a randomized design with consistent products and doses?
Read the original research
Measuring the Effects of Cannabis on Anxiety and Depression Among Cancer Patients.
Cancer medicine, 14(21), e71342
Cancer Medicine is a reputable journal focused on oncology research.
Citation
Reddy, Apoorva C; Hampton, John M; Park, Susan J; Dickerson, Faith; Shah, Janvi; Chewning, Betty; Schmitz, Natalie; Trentham-Dietz, Amy. (2025). Measuring the Effects of Cannabis on Anxiety and Depression Among Cancer Patients.. Cancer medicine, 14(21), e71342. https://doi.org/10.1002/cam4.71342
Explore the wider topic
- Weed Withdrawal Anxiety in Public: When Leaving the House Feels Impossible
- The DARE Response to Anxiety for Cannabis Withdrawal
- The Cannabis Withdrawal Anxiety Toolkit: Quick Techniques That Work
- Why Anxiety Gets Worse Before It Gets Better After Quitting Weed
- Breathing Exercises for Weed Withdrawal Anxiety
- Cannabis-Induced Anxiety: When Weed Stops Being Fun
- Does Weed Help or Hurt Anxiety? What Research Actually Shows
- Grounding Techniques for Cannabis Withdrawal: A Practical Toolkit
- Quitting Weed with Health Anxiety: Why Every Symptom Feels Like a Crisis
- How to Manage Anxiety Without Weed: 15 Evidence-Based Alternatives
- Quitting Weed with Anxiety Disorder: A Careful Approach
- Quitting Weed When You're on Anxiety Medication: What to Know
- Self-Medicating Anxiety with Weed: Why It Works Until It Doesn't
- Do I Need Therapy to Quit Weed? When Professional Help Makes Sense
- Weed and Anxiety: The Paradox That Traps People
- The Biphasic Effect: Low-Dose Calms, High-Dose Panics
- Weed and Generalized Anxiety Disorder (GAD): Why It Backfires
- Weed and Panic Attacks: The Connection Nobody Talks About
- Weed and Paranoia: When Cannabis Turns Your Mind Against You
- Weed and Social Anxiety: Why It Feels Like the Only Thing That Helps
- Why Weed Stopped Working for Your Anxiety
- Weed Withdrawal Anxiety: Understanding the Panic and How to Cope
- Weed Withdrawal Panic Attacks at Night: Why They Happen and How to Get Through Them
- Going Back to Work During Weed Withdrawal: Managing Anxiety and Staying Functional
- Withdrawal Anxiety vs Pre-Existing Anxiety: How to Tell the Difference